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Abstract Hip fracture is associated with high morbidity,
mortality, and economic burden worldwide. It is also a
major risk factor for a subsequent fracture. A literature
search on the management of osteoporosis in patients with
hip fracture was performed on the Medline database. Only
one clinical drug trial was conducted in patients with a
recent hip fracture. Further studies that specifically address
post-fracture management of hip fracture are needed. The
efficacy of anti-osteoporosis medication in older individuals
and those at high risk of fall is reviewed in this paper.
Adequate nutrition is vital for bone health and to prevent
falls, especially in malnourished patients. Protein, calcium,
and vitamin D supplementation is associated with increased
hip BMD and a reduction in falls. Fall prevention, exercise,
and balance training incorporated in a comprehensive
rehabilitation program are essential to improve functional
disability and survival. Exclusion of secondary causes of
osteoporosis and treatment of coexistent medical conditions
are also vital. Such a multidisciplinary team approach to the
management of hip fracture patients is associated with a
better clinical outcome. Although hip fracture is the most
serious of all fractures, osteoporosis management should be
prioritized to prevent deterioration of health and occurrence
of further fracture.
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Introduction
A hip fracture that occurs in the context of a low-energy
trauma constitutes a fragility fracture. It represents the most
serious complication of osteoporosis and the most severe
form of osteoporotic fracture. Survival and quality of life
decrease significantly following hip fracture and five-year
excess mortality increases by about 20% [1]. Elderly
patients with previous history of hip fracture are at very
high risk of further fractures: a 2.5-fold increased risk of
vertebral fracture and 2.3-fold risk of future hip fracture [2].
The incidence of hip fracture increases exponentially with
age in women between 60 and 85 years, but thereafter more
slowly [3]. The vast majority of hip fractures thus occur in
elderly individuals, many of them in residential care where the
risk of hip fracture is 2-fold to 11-fold that of individuals
living in the general community [4–8]. Within a year of
sustaining a hip fracture, an elderly nursing home resident
has a 40% risk of death and a 6% to 12% risk of further hip
fracture [9, 10] This high incidence of re-fracture is likely
related to a very high risk of falls in such individuals: 98% of
hip fractures are the result of fall, the proportion of vertebral
fractures is lower [11, 12]. The risk of fracture seems to be
determined by a balance between bone strength and
propensity for falls, which in term are determined by the
frailty of the patient [13].
Hip fractures are easy to diagnose. Thus neither the
National Osteoporosis Society (in the UK) nor the
National Osteoporosis Foundation (NOF, in the US)
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advises application of the World Health Organization
fracture risk assessment tool FRAX for treatment
decisions in patients with fragility fracture. The NOF
(in the US) advocates drug treatment in such patients
without the need for bone mineral density (BMD)
measurement, except in young postmenopausal women
[14]. The National Osteoporosis Guideline Group of UK
recommends BMD measurement in patients aged between
60 and 80 years [15]. It should nonetheless be emphasized
that treatment decisions should not be hampered by the
unavailability of dual-energy X-ray machines for BMD
measurement. A focus on BMD measurement prior to the
initiation of anti-osteoporotic treatment in patients with a
known history of fracture may result in missed opportu-
nities for treatment. Thus patients with hip fracture and
satisfactory quality of life warrant treatment to prevent
future fractures. Unfortunately, the proportion of hip
fracture patients prescribed with osteoporosis drugs
remains low. In a report from Belgium, just 6% of
previously untreated patients hospitalized for hip fractures
were prescribed anti-osteoporotic therapy, with only 41%
continuing treatment at 12 months: median treatment
duration was 40 weeks [16]. Similarly, in a nationwide
survey of 53,325 patients admitted with hip fracture to 318
hospitals in the US, only 6.6% were prescribed calcium
and vitamin D, and 7.3% anti-resorptive or bone-forming
agents [17].
Despite limited data, there is apparently sufficient
evidence to support initiation of pharmacological treatment
for secondary fracture prevention in hip fracture patients.
The objective of osteoporosis treatment is to decrease the risk
of re-fracture. Additional benefits include improved quality of
life, decreased risk of falls, and reduced mortality. Medical
intervention includes non-pharmacological interventions,
correction of reversible and secondary causes of bone loss,
and anti-osteoporosis medication.
Non-pharmacological prevention of fractures
Nutrition and protein intake
Adequate nutrition is vital for bone repair and to prevent
further falls but malnutrition is common in older men and
women hospitalized for hip fracture [18]. A low score on
the Mini-Nutritional Assessment is associated with a
twofold increased risk of osteoporosis [19]. The relation
between dietary protein intake and bone health is nonethe-
less controversial: diets high in protein have generally been
considered to have adverse effects on bone health because
the associated acid load may release calcium from the
skeleton and cause bone loss. Darling et al. (2009) recently
conducted a systematic review and meta-analysis of both
cross-sectional and prospective studies to clarify the
relation between dietary protein intake and bone health in
healthy adults [20]. No negative relation was identified
between dietary protein and bone: there was a slight
positive association between increasing dietary protein and
BMD. Protein supplementation led to a 1% to 2% increase
in BMD at the lumbar spine, but there was no strong
evidence for a reduced risk of hip fracture. In older
individuals with poor oral intake and low protein consump-
tion, a healthy diet that included dairy products (mainly fat
free), fruit and vegetables, and adequate amounts of meat,
fish, and poultry nonetheless increased insulin-like growth
factor I, an enzyme positively related to musculoskeletal
health [21]. The Framingham Osteoporosis Study studied
946 elderly men and women and observed that individuals
with a protein intake at the upper quartile had a 37%
decreased risk of hip fracture [22]. Data from large
prospective studies are nevertheless needed to confirm this
finding. Although the effect on fracture prevention is
controversial, a balanced diet with adequate protein intake
can prevent weight loss, muscle wasting, and sarcopenia—
important risk factors for frailty and falls.
Calcium and vitamin D supplementation
Vitamin D deficiency or insufficiency is common in the
elderly hip fracture patients. Vitamin D is rare in food. The
major source of Vitamin D is synthesis of cholecalciferol
(Vitamin D3) from its precursors in the skin under the effect
of ultraviolet light. Vitamin D insufficiency is more
prevalent in older subjects due to less efficient synthesis
of Vitamin D3 in the skin [23], decreased renal production
of 25OHD [24] and decreased gastrointestinal absorption of
calcium in response to 1,25OHD [25].
Vitamin D deficiency is defined in the presence of
osteomalacia (25OHD<25 nmol/L), while insufficiency is
defined as the occurrence of secondary hyperparathyroid-
ism with 25OHD 25 to 50 nmol/L [26]. The optimal serum
25(OH)D is 50 to 80 nmol/L [27]. The prevalence of
vitamin D insufficiency and suboptimal serum 25(OH)D
among the older population is around 30–50% in most parts
of the world [28–31].
Vitamin D is the key to intestinal absorption of calcium,
and hence ensuring calcium and vitamin D sufficiency
forms a pivotal part of the fracture prevention management
protocol. Calcium and vitamin D supplementation improves
bone mineralization, reduces bone resorption, corrects
secondary hyperparathyroidism and prevents falls [26].
There is also evidence that calcium and vitamin D enhance
the anti-fracture efficacy of bisphosphonate agents. Of note,
patients in pivotal studies of all anti-osteoporotic agents
received calcium and vitamin D supplementation. Thus
calcium and vitamin D supplementation is a key component
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in the prevention and treatment of osteoporosis unless
calcium intake and vitamin D status are known to be
optimal.
The difficulty in interpreting studies on the use of
calcium and vitamin D for fracture prevention is related to
the heterogeneity of studies in terms of study population,
treatment doses, preparations, and combinations, baseline
calcium and vitamin D intake, baseline 25OHD levels, and
compliance with treatment.
A number of randomized clinical trials have attempted to
determine the effect of vitamin D and calcium on fracture
prevention. Early studies performed among institutionalized
subjects with a mean age of 84 years showed that use of
daily vitamin D3 800 IU and 1,200 mg calcium resulted in
a significant reduction in hip fracture with a relative risk of
43% [32]. In contrast, community-based randomized
controlled clinical trials that recruited patients with >1 risk
factor for fracture [33] or a history of low-trauma fracture
[34] with a mean age of 77 years, and supplemented with
daily vitamin D3 800 IU and calcium 1,000 mg demon-
strated no reduction in hip fractures or total fractures.
Nonetheless the hip fracture rate was noted to be low for
the two studies: <1% for all groups [33] and 4% overall
[34]. In addition, in the Women's Health Initiative study of
elderly women (mean age 66 years old) who were
randomized to receive daily vitamin D3 400 IU and
calcium 1,000 mg, there was no reduction in hip fracture
rate with hazard ratio of 0.88 (95% CI 0.72,1.08) [35].
A meta-analysis, employing a random effect model and
involving 63,897 subjects (mean age of 67.8±9.7 years)
revealed that calcium supplementation with or without
vitamin D was associated with a 12% risk reduction in
fractures of all types (95% CI 0.83, 0.95) [36]. The
treatment effect was better in institutionalized than in
community-dwelling subjects (RR 0.76 vs 0.94), those
with low daily calcium intake (<700 mg/day) and older
age >70 years. The estimated number needed to treat
(NNT) to prevent one fracture was 63. Another system-
atic review that employed a fixed effect model demon-
strated that a combination of Vitamin D and calcium
resulted in an overall reduction in hip fracture with risk
ratio of 0.84 (95% CI 0.73, 0.96). Risk ratio was lower
for institutionalized than community-dwelling subjects
(0.75 vs 0.91) [37]. Another meta-analysis that employed
a random effect model and involved 9,083 subjects
demonstrated that combined vitamin D and calcium could
reduce hip fracture incidence by 25% (95%CI 4,42). The
estimated NNT to prevent one fracture was approximately
276 [38]. In addition, two meta-analyses revealed that use
of Vitamin D alone in comparison with placebo did not
result in hip fracture reduction [37, 38].
Better compliance results in better risk reduction of total
or hip fracture. In a meta-analysis, studies with >80%
compliance resulted in a doubling of risk reduction, 24%
vs 12% of total fractures [36]. In the Women's Health
Initiative (WHI) study, analysis of data excluding follow-
up time for subjects 6 months following detection of non-
compliance showed an increase in risk reduction of hip
fracture by 29% (versus 12% when using ITT analysis)
[35].
The minimal level of serum 25OHD for fracture
prevention is considered to be 30 to 80 nmol/L, and
supplementation with Vitamin D is recommended to be
800 to 1,000 IU per day to achieve a serum 25 OHD
level of 75 nmol/L [26]. A meta-analysis showed that
vitamin D may have a dose-dependent effect: pooling
trials with a higher received dose of >400 IU/day,
heterogeneity of the studies was resolved and a relative
reduction in hip fracture of 18% was demonstrated (95%
CI, 0.69–0.97) [39]. Analysis also showed that for both
hip and non-vertebral fractures, the anti-fracture efficacy
increased significantly with a higher received dose
(metaregression: ß=−0.001; P=.07) and higher achieved
25-hydroxyvitamin D levels (metaregression: ß=−0.009;
P=.01). The received dose of vitamin D was determined
from cross-product of dose and percentage compliance
with supplementation.
Most studies of calcium supplementation prescribe a
daily calcium dose of 1,000–1,200 mg [32–35]. In
contrast to vitamin D supplementation, meta-analysis of
prospective cohort studies and clinical trials did not show
a higher fracture risk reduction with a higher calcium
intake [40]. In addition, a randomized controlled trial of
elemental calcium supplementation at a dose of 1,000 mg/
day showed an increase in relative risk of 47% (95% CI
0.97, 2.23) in combined cardiovascular endpoints (defined
as sudden death, myocardial infarction, angina, or chest
pain) when compared with placebo [41]. In the WHI study,
those who received calcium 1,000 mg daily had a 17%
increase in the incidence of renal stones or renal
insufficiency compared with placebo group [35]. At
present, the exact calcium requirement remains a matter
for debate although a total daily calcium intake (diet plus
supplementation) of approximately 1,000 mg/day is likely
to be sufficient and safe.
Relationship between vitamin D, falls and fracture
prevention
Approximately 5% to 10% of all falls will result in a
fracture and 90% of all fractures are results of falls [42, 43].
A low level of vitamin D is associated with an increased
incidence of falls in the elderly [44, 45]. Possible
mechanisms include the effect of vitamin D on calcium
homeostasis, muscle strength [46], and physical perfor-
mance [47, 48]. An increased risk of fall occurs when 25
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(OH)D falls below 25 nmol/L [49]. Body sway is also
noted to increase when 25(OH)D falls below 50 nmol/L
[50]. Lower limb physical performance declines markedly
when serum 25(OH)D falls below 50 nmol/L [47].
Interestingly, systematic review demonstrates that use
of vitamin D, alone or in combination with calcium, does
not significantly reduce falls (both rate of falls or number
of fallers) or incidence of fracture following fall [51].
Nonetheless, subgroup analysis reveals that falls can be
reduced in those with low-baseline 25(OH)D level with
risk ratio of 0.57 (95% CI 0.37,0.89) compared with those
with high-baseline 25(OH) D and risk ratio of 1.02 (95%
CI, 0.88,1.19) [51]. Another meta-analysis of pooled data
from seven randomized controlled trials that recruited
1,921 subjects demonstrated that use of Vitamin D 700–
1,000 IU daily could reduce falls with a risk ratio of 0.81
(95% CI 0.71,0.92). In addition, subjects who achieved a
25(OH)D level >60 nmol/L had reduced falls with a risk
ratio of 0.77 (95% CI 0.65,0.90), compared with those
with level <60 nmol/L and risk ratio of 1.35 (95% CI
0.98,1.84) [52].
It is known that vitamin D is stored in fat and that the
half life of 25(OH)D is 3 weeks. Thus vitamin D
supplementation can be given every month or 4 to 6 months.
Clinical study demonstrates a reduction in total fracture
following prescription of 100,000 IU vitamin D orally
every 4 months in community-dwelling subjects with a
relative risk of 0.78 (95% CI, 0.61,0.99) [53]. A yearly
regimen was noted to be undesirable. Another study that
administered vitamin D2 300 000 IU by intramuscular
injection during the autumn did not result in reduction in
relative risk of first fracture, but significantly increased the
risk of first hip fracture [54]. A recent study of oral vitamin
D 500,000 given yearly during autumn or winter to the
elderly with mean age 76 years old, for a median follow-up
of around 3 years, demonstrated that the active group had
an increased incidence of fractures with relative risk of 1.26
(95% CI 1.00, 1.59) and also an increased incidence of falls
with relative risk of 1.15 (95% CI 1.02, 1.30) [33]. Of
interest, there was an increased incidence of fractures and
falls in the first 3 months after yearly oral intake compared
with month 4 to12 months [55].
Vitamin D metabolites including 1-alpha cholecalciferol
(alphacalcidol) and 1,25-dihydroxycholecalciferol (calci-
triol) are used in some Asian countries with positive results
on hip fracture prevention, although the studies are small
and the effect on BMD improvement is controversial [56,
57]. The effect on fracture reduction is partly mediated by a
reduced incidence of falls because of improved muscle
strength and neuromuscular coordination. These agents
nonetheless increase intestinal calcium absorption pharma-
cologically and have a low margin of safety with a risk of
hypercalcaemia and hypercalciuria.
Pharmacological management: consideration in hip
fracture patients
Currently available anti-osteoporosis therapies include
hormone therapy (HT), calcitonin, selective estrogen
receptor modulators (SERMs), bisphosphonates, parathy-
roid hormone (PTH), and strontium ranelate. HT and
calcitonin have become unpopular in the last 10 years:
HT imposes an unnecessary health risk to postmenopausal
women especially in older women [58], and calcitonin has
inconsistent or uncertain anti-fracture efficacy, especially
for non-vertebral fractures [59].
Most randomized controlled studies of anti-osteoporosis
drugs have not focused on hip fracture patients, partly
because they tend to be frail elderly who constitute a
challenge in terms of study design. The inclusion criteria
have been generally based on a history of vertebral fracture
and/or a BMD that fulfills the World Health Organization
(WHO) working definition of osteoporosis. In this context,
despite the availability of a wide spectrum of anti-
osteoporosis drugs, there is a significant paucity of
evidence-based literature to guide treatment of this older
patient population with hip fracture.
Efficacy of anti-osteoporosis drugs in patients with hip
fracture
The most compelling evidence to support anti-osteoporosis
treatment in hip fracture patients comes from zoledronic
acid, a bisphosphonate. The Health Outcomes and Reduced
Incidence with Zoledronic Acid Once Yearly (HORIZON)
Recurrent Fracture Trial (RFT) was a secondary prevention
study that involved 1,065 subjects (75% women) with mean
age 75±9 years and incidental hip fracture. Zoledronic acid
at a dose of 5 mg administered as a yearly 15-minute
intravenous infusion with the first dose being given within
90 days after hip fracture surgery significantly reduced any
new clinical fracture by 35%, clinical vertebral fracture by
46% and non-vertebral fracture by 27% after a mean
follow-up of 1.9 years. Risk of hip fracture was reduced by
30% but this was not significant due to the low number of
events [60]. There was also a significant 28% reduction in
all-cause mortality in the active treatment group [60].
Though the exact underlying mechanism responsible for
this improved survival has yet to be elucidated, an
exploratory analysis showed that zoledronic acid-treated
subjects were less likely to die from pneumonia and
arrhythmias than placebo-treated subjects [61].
A pivotal study of Zoledronic acid, the HORIZON
Pivotal Fracture Trial, that involved 3,889 postmenopausal
osteoporotic women with a mean age of 73±5 years (38%
were >75 years of age) also showed a significant 70%
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reduction in the incidence of morphometric vertebral
fracture, a 25% reduction in non-vertebral fracture, and a
41% reduction in hip fracture at 36 months [62]. Subgroup
analysis in subjects aged ≥75 years was not available.
Significant anti-fracture efficacy at the spine in the
elderly population was also evident for two other
bisphosphonates, alendronate, and risedronate. Pooled
analysis of the combined data of 1,392 women ≥80 years
of age (mean age 83±3 years) from the three major phase
three clinical trials of risedronate showed that risedronate
5 mg daily significantly reduced the risk of new vertebral
fracture by 81% at 1 year and 44% at 3 years. The NNT
were 12 and 16 after 1 and 3 years, respectively. The
reduction in risk of non-vertebral fracture was nonetheless
not significant at either time point [63].
In a subgroup analysis of 539 women aged ≥75 years
(range 75–82 years) in the Fracture Intervention Trial,
alendronate significantly reduced new vertebral fracture by
38% at 3 years. The corresponding NNT was 13. Data on
non-vertebral fracture reduction were unavailable [64].
Agents with bone-forming properties, teriparatide and
strontium ranelate, have also shown evidence of fracture
risk reduction in older patients. A pre-planned analysis of
the pooled data of 1,488 women 80–100 years of age from
the SOTI and Treatment of Peripheral Osteoporosis
(TROPOS) studies showed that strontium ranelate at a
dose of 2 g daily achieved a significant 59% risk reduction
in vertebral fracture, 41% risk reduction in non-vertebral
fracture, and 37% risk reduction in clinical fracture at
1 year. The corresponding risk reductions were 32%, 31%,
and 21%, respectively, at 3 years [65]. In the TROPOS
study, strontium ranelate additionally showed a significant
36% risk reduction in hip fracture at 3-years in a post-hoc
analysis of a high-risk subgroup of women with age ≥74 years
and femoral neck BMD T-score<−3 [66].
In a pre-specified subgroup analysis of the Fracture
Prevention Trial (FPT), teriparatide demonstrated a 59%
reduction in risk of new vertebral fracture at 1 year in 244
women with age ≥75 years (range 75–86 years) and ≥1
moderate vertebral fracture or two mild vertebral fractures
at baseline. The risk reduction in non-vertebral fracture was
nonetheless not significant [67]. Since the FPT was
terminated early with median treatment duration of
19 months, longer-term data on fracture risk reduction are
unavailable [67].
The SERM, raloxifene, has not demonstrated a positive
effect on non-vertebral fracture reduction in clinical studies
[68] and its anti-fracture efficacy at the spine in the older
age group has not been adequately addressed. The newer
SERM, bazedoxifene, at a dose of 20 mg daily has shown a
significant 50% risk reduction in non-vertebral fracture at
3 years in a post-hoc analysis of a higher-risk subgroup of
1,772 women with femoral neck T-score≤−3.0 and/or ≥1
moderate or severe vertebral fracture or multiple mild
vertebral fractures [69]. The age of this higher-risk
subgroup was not specified.
Denosumab, a fully human monoclonal antibody that
specifically binds to the receptor activator of nuclear factor-
kappa B ligand (RANKL) was recently developed as a new
anti-resorptive agent with a novel mechanism of action. Given
as a subcutaneous injection at a dose of 60 mg every 6 months
for 36 months in the FREEDOM trial, denosumab signifi-
cantly reduced the risk of new radiographic vertebral fracture
by 68%, the risk of hip fracture by 40% and the risk of non-
vertebral fracture by 20% in 7,868 postmenopausal osteopo-
rotic women of age 60 to 90 years [70]. Whether this potent
anti-resorptive agent will have specific benefit to the elderly
or hip fracture patients requires further study.
In conclusion, although hip fracture is the most common
fracture in patients who live beyond their 70s, there is
limited evidence to guide treatment of osteoporosis in these
patients. Nonetheless, it is reasonable to prescribe anti-
osteoporosis drugs to such high-risk patients based on the
assumption that they will respond to treatment in a similar
manner to other more well-defined groups of osteoporotic
patients in clinical trials, who are of younger age with or
without prior vertebral fracture. Zoledronic acid appears to
be the only agent that demonstrates both vertebral and non-
vertebral fracture risk reduction as well as survival benefit
in the fracture hip population. With regards general anti-
fracture efficacy in the elderly, risedronate, strontium
ranelate, and teriparatide all provide evidence of early risk
reduction of vertebral fracture at 1 year with benefits
sustained to 3 years for risedronate and strontium ranelate.
Alendronate provides evidence of vertebral fracture risk
reduction at 3 years only. Anti-fracture efficacy at non-
vertebral sites was only provided by strontium ranelate at
both time points in women aged ≥80 years.
Effect of anti-osteoporosis drugs on fracture healing
Whether fracture healing is affected or not by anti-
osteoporosis treatment is one of the most important
concerns of the orthopedic surgeon, in particular with
regard to bisphosphonates that suppress bone-turnover.
Animal models of fracture demonstrate that bisphospho-
nates delay remodeling of callus, which became larger in
size but stronger in structural strength [71, 72]. Raloxifene
and estrogen have no major effect on fracture healing [72].
Well-designed randomized clinical trials in humans to
address this important issue are lacking. A small cohort study
that compared radiographic fracture healing of the distal
radius in 43 patients prescribed bisphosphonate therapy at the
time of fracture with 153 control subjects revealed that
bisphosphonate use was associated with a longer time to
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radiographic union (55±17 days vs 49±14 days). The
differences in healing time were nonetheless small (<1 week)
and considered clinically insignificant [73].
The best reassuring piece of clinical evidence in hip
fracture patients is provided again by the HORIZON RFT in
which zoledronic acid infusion was given within 90 days of
hip fracture repair. The incidence of delayed union was 34
(3.2%) in the zoledronic acid group and 29 (2.7%) in the
placebo group (risk ratio 1.17; 95% CI 0.72–1.90; P=0.61)
[60]. There was no clinical evidence of impaired facture
healing with early administration of a potent bisphosphonate.
For bone-forming agents, teriparatide, by virtue of its
stimulatory effect on bone formation, has been reported to
accelerate remodeling, improve material properties, and
enhance fracture healing in animal models [74–76].
Strontium ranelate also significantly increases bone forma-
tion, BMD, biomechanical strength, and improves micro-
structural properties of the callus in a rat model [77]. A
direct comparison study using an osteoporotic rat model of
fracture healing showed that strontium ranelate enhances
callus strength more than teriparatide [78].
Although findings in animal models cannot be extrapo-
lated to humans, there appear to be no suggestions of a
negative effect on fracture healing with anti-osteoporosis
drug treatment. In a recent multidisciplinary workshop of
the International Society for Fracture Repair, leading
experts carried out an extensive review of the literature
and reached a consensus that there is no evidence-based
reason to withhold anti-resorptive therapy while a fracture
heals, whether or not the patient is taking such therapy
when the fracture occurs [79]. It recommended that
secondary prevention should be implemented as soon as
possible after a fragility fracture and at least prior to
discharge from an acute fracture ward [79].
This consensus has vital clinical implications in the
management of patients with fracture. Currently, the
majority of patients with a history of fracture fail to receive
effective anti-osteoporosis treatment for secondary preven-
tion [80] and of those who have been treated with oral
bisphosphonates, the rate of adherence to therapy is very
suboptimal with an overall 1-year persistence rate ranging
from 17.9% to 78.0% despite the use of more convenient
weekly preparations [81]. The acute presentation of patients
with fragility fracture, notably hip fracture, should provide
a great opportunity for clinicians to commence secondary
prevention at this important “signal” fracture stage, which
may improve persistence and compliance with treatment.
Effect of anti-osteoporosis drugs on survival
Hip fractures are associated with the highest degree of
morbidity and mortality of all fractures with an associated
1-year mortality up to 15–25%. The HORIZON RFT was
the first study in the literature to show a reduction in
mortality when anti-osteoporosis drug therapy was com-
menced following a hip fracture. There was a 28%
reduction in mortality in the active treatment group after a
mean follow-up of 1.9 years [60]. An exploratory analysis
showed that its impact on mortality was mediated only to a
small extent (8%) through its fracture reduction benefit and
zoledronic acid-treated subjects were less likely to die from
pneumonia and arrhythmias than placebo-treated subjects
[61]. The mechanism for this finding is currently unknown
but may relate to the anti-inflammatory, anti-angiogenic,
and immuno-modulatory effects of bisphosphonates [61].
Since the individual trials of other anti-osteoporosis
drugs were not powered to detect mortality difference, a
meta-analysis of >40,000 subjects in ten placebo-controlled
randomized studies of five agents (alendronate, risedronate,
strontium ranelate, zoledronic acid, and denosumab) was
performed. Results showed that treatment of osteoporosis
was associated with a significant 10% reduction in
mortality [82]. A 10% relative risk reduction corresponds
to an absolute mortality benefit ranging from 0.4 to seven
deaths prevented per 1,000 patient-years of treatment. This
mortality reduction was mainly observed in studies of older,
frailer individuals at high risk of fracture [82]. The
consolidation of a survival benefit from treatment of
osteoporosis and the absence of a negative effect on
fracture healing should further encourage early anti-
osteoporosis drug treatment in patients with hip fracture.
Exclusion of secondary causes for osteoporosis
All patients with fracture should be carefully evaluated to
exclude secondary osteoporosis. Such evaluation should
include a thorough history, physical examination, bone
mineral density testing, and laboratory testing. While there
is no consensus on the most cost-effective laboratory
evaluation, general recommendations include measurement
of serum 25-hydroxyvitamin D, PTH, complete blood
count, serum and urine calcium, phosphate, renal and liver
function tests, thyroid-stimulating hormone, and testoster-
one in men.
Vitamin D insufficiency is a common cause of bone loss
in the elderly. Approximately 50% of men with osteoporo-
sis have an underlying risk factor for bone loss [83]. Apart
from the well-recognized association with glucocorticoids,
an increasing list of drugs has been implicated in bone loss
and fractures. Osteoporosis related to hormonal deprivation
therapy such as anti-androgenic therapy for prostate cancer
and aromatase inhibitor therapy for breast cancer is an
important area that has been overlooked in the past.
Clinicians have a significant responsibility to evaluate and
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treat any underlying medical problem that causes bone loss
and to optimize bone health in the individual patient. With
appropriate consideration of secondary causes and relevant
investigations and newer therapies, many of these con-
ditions can be prevented.
Treatment of pre-existing medical problems
Pre-existing medical problems are often the facilitating
factors for fractures and important determinants for mor-
bidity, mortality, and final outcome in patients with hip
fracture. Cardiopulmonary and neurological disorders are
the most frequent medical diseases in these elderly hip
fracture patients. The presence of ischemic heart disease,
heart failure, cardiac arrhythmia, hypertension, chronic
obstructive airways disease, pneumonia, or cerebrovascular
disease confer the most risk for complications and
difficulties during anesthesia, surgery, immediate postoper-
ative recovery, and rehabilitation. Other major diseases
include diabetes, cataract, dementia, depression, and psy-
chosis. Adopting a multidisciplinary approach to manage-
ment with consequent attention to these conditions during
the perioperative period may reduce postoperative compli-
cations and mortality. A meta-analysis of nine studies that
involved 4,637 patients demonstrated lower odds of deep
venous thrombosis, pressure ulcer, surgical site infection,
and urinary tract infection in patients managed according to
clinical pathways than in those receiving usual care [84].
Preventing frailty and falls
Non-pharmacological therapies consist of education about
osteoporosis and fracture prevention; lifestyle advice and
modifications; optimization of nutritional, calcium and
vitamin D intake; fall preventive measures. There is
evidence that a multidisciplinary approach to the care of
patients with hip fracture is associated with a higher pick-
up rate of treatment and significantly lower re-fracture and
mortality rates [85]. Over 98% of hip fractures are
associated with falls and fall has been consistently shown
to be one of the most important underlying risk factors. A
pro-active approach to prevent falls should receive at least
as much attention as drug therapy for osteoporosis in hip
fracture patients, but is often an area of care that is
neglected. The concept of frailty has received increasing
attention in recent years as neither BMD nor clinical risk
factors such as age and weight can capture fully the risk of
osteoporotic fractures in elderly. Frailty is a state of poor
well being, related to muscle weakness and sarcopenia,
poor endurance, a low level of physical activity and easy
exhaustion and with a slowness of gait [86]. Physical
activity and exercise form part of the post-hip fracture
rehabilitation but in the elderly, also serve to increase
muscle mass and strength, improve body function, reduce
risk of fall, and contribute to a better quality of life.
Immobilization accelerates bone loss and should be avoided
as far as possible. Nonetheless the minimal level of
physical activity and exercise required to prevent bone loss
remains a matter for debate [87]. Exercises that improve
balance, including Tai-Chi, reduce the incidence of falls and
fall-related injuries in community-dwelling, physically
inactive individuals of mean age 77 years [88] but do not
reduce the risk of fracture. In a meta-analysis of four studies
that involved community-dwelling individuals aged 65 to
97 years, a home exercise training program reduced falls
and fall-related injuries, with the effect being more
pronounced in participants aged 80 years and above [89].
In hip fracture patients with reduced mobility and poor
balance, careful evaluation is required before exercise is
prescribed: without adequate balance training the subject
may be at higher risk of falls and hence fractures.
In post-hip fracture subjects with poor mobility, poor
motivation, and easy fatigability, whole-body vibration is a
potential promising alternative to conventional exercise.
Whole-body vibration can induce gain in muscle strength
similar to that achieved with conventional resistance
training. It also improves BMD in postmenopausal women
[90]. Data on fall prevention and reduction in fracture risk
are as yet unavailable. The benefit of wearing hip protectors
in hip fracture prevention is controversial as patient
compliance is often a problem and study results thus
unreliable. Recent systemic review and meta-analysis failed
to confirm the effect of hip protectors in community-
dwelling subjects or nursing home residents [91, 92].
Medical risk factors that predispose the elderly to fall
should be identified and treated. These include correction of
cataract and other causes of visual impairment, evaluation
of gait and balance, and avoidance of sedatives or
medications that may affect balance and stability. Elderly
individuals who are physically unstable should be pre-
scribed appropriate walking aids and gait-training exercises.
Assessment of home and environmental safety is often
neglected and should be emphasized. In individuals who
require assistance with daily activities, care-providers
should be educated on the correct technique in the transfer
of elderly to avoid fall and fall-related injuries.
Conclusion
Hip fracture is a major problem in the elderly population
that creates a huge medical and economic burden world-
wide. Patients with hip fractures are at high risk of future
fracture and proper management is vital to reduce the
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associated impact on quality of life and mortality and to
prevent the risk of future fractures.
Very few studies have investigated the anti-fracture
efficacy of osteoporosis medication in patients with hip
fractures, and more data are required to better define their
optimal treatment. Non-pharmacological treatment, includ-
ing adequate nutrition, calcium, and vitamin D intake
together with exercise and rehabilitation programs form a
vital part of the treatment regimen in these frail elderly
patients. Recent data suggest that a multidisciplinary team
that provides holistic evaluation and medical care before
and after surgery and throughout the rehabilitation process
is associated with a better patient outcome. Although hip
fracture is the most serious complication of osteoporosis,
active implementation of appropriate treatment can provide
better outcome in terms of survival and re-fracture rates.
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